N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl] amino]methyl]-phenyl]-2-propenamide (NVP-LAQ824)

Journal of Medicinal Chemistry

Volumn 46, Issue 21, 2003, Pages 4609-4624

  Remiszewski, Stacy W ^a,b   Sambucetti, Lidia C ^a,c   Bair, Kenneth W ^a,d   Bontempo, John ^a   Cesarz, David ^a   Chandramouli, Nagarajan ^a   Chen, Ru ^a   Cheung, Min ^a   Cornell Kennon, Susan ^a   Dean, Karl ^a   Diamantidis, George ^a   France, Dennis ^a   Green, Michael A ^a   Howell, Kobporn Lulu ^a   Kashi, Rina ^a   Kwon, Paul ^a   Lassota, Peter ^a   Martin, Mary S ^a   Mou, Yin ^a   Perez, Lawrence B ^a   Sharma, Sushil ^a   Smith, Troy ^a   Sorensen, Eric ^a   Taplin, Francis ^a   Trogani, Nancy ^a   Versace, Richard ^a   Walker, Heather ^a   Weltchek Engler, Susan ^a   Wood, Alexander ^a   Wu, Arthur ^a   Atadja, Peter ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c Xenogen Corporation   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; AMIDE; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; MITOMYCIN C; N HYDROXY 3 [4 [[(2 HYDROXYETHYL)[2 (1H INDOL 3 YL)ETHYL]AMINO]METHYL]PHENYL] 2 PROPENAMIDE; N HYDROXY 3 PHENYL 2 PROPENAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; RAT STRAIN; TUMOR CELL; XENOGRAFT;

ACETYLTRANSFERASES; ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HISTONE ACETYLTRANSFERASES; HUMANS; HYDROXAMIC ACIDS; INDICATORS AND REAGENTS; MICE; MICE, NUDE; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 10744229917     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030235w     Document Type: Article

References (35)

1. Wu, J.; Grunstein, M. 25 years after the nucleosome model: chromatin modifications. Trends Biochem. Sci. 2000, 25, 619-623.
2. Eberharter, A.; Becker, P. B. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002, 3, 224-229.
3. Roth, S. Y.; Denu, J. M.; Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70, 81-120.
4. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.
5. Khochbin, S.; Verdel, A.; Lemercier, C.; Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 2001, 11, 162-166.
6. Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
7. Archer, S. Y.; Hodin, R. A. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 1999, 9, 171-174.
8. Remiszewski, S. W. Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Discovery Dev 2002, 5, 487-499.
9. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 2001, 8, 1505-1511.
10. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery 2002, 1, 287-299.
11. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
12. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
13. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
14. Jung, M.; Hoffmann, K.; Brosch, G.; Loidl, P. Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 1655-1658.
15. Remiszewski, S. W.; Sambucetti, L. C.; Atadja, P.; Bair, K. W.; Cornell, W. D.; Green, M. A.; Howell, K. L.; Jung, M.; Kwon, P.; Trogani, N.; Walker, H. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 2002, 45, 753-757.
16. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
17. Jung, M.; Brosch, G.; Koelle, D.; Scherf, H.; Gerhaeuser, C.; Loidl, P. Amide analogues of trichostatin a as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 1999, 42, 4669-4679.
18. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 2001, 3, 4239-4242.
19. Saigo, K.; Sukegawa, M.; Maekawa, Y.; Hasegqwa, M. Topochemical photopolymerization of 4-[2-(unsubstituted and methyl-substituted pyrazinyl)ethenyl]cinnamates and -thiocinnamates in the crystalline state. Bull. Chem. Soc. Jpn. 1995, 68, 2355-2362.
20. Ono, S.; Yoshida, T.; Maeda, K.; Kosaka, K.; Inoue, Y.; Imada, T.; Fukaya, C., Nakamura, N. Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives. Chem. Pharm. Bull. 1999, 47, 1694-1712.
21. Umino, N.; Iwakuma, T.; Itoh, N. Sodium acyloxyborohydrides as new reducing agents. 1. Reduction of carboxamides to the corresponding amines. Tetrahedron Lett. 1976, 763-766.
22. Sambucetti, L. C.; Fischer, D. D.; Zabludoff, S.; Kwon, P. O.; Chamberlin, H.; Trogani, N.; Xu, H.; Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 1999, 274, 34940-34947.
23. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589-601.
24. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T. ; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4592-4597.
25. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives. J. Med. Chem. 1999, 42, 3001-3003.
26. Cuadro, A. M.; Matia, M. P.; Garcia, J. L.; Vaquero, J. J.; Alvarez-Builla, J. Synthesis of N-(aminoethyl)azoles under phase transfer catalysis. Synth. Commun. 1991, 21, 535-544.
27. Kuehne, M. E.; Huebner, J. A.; Matsko, T. H. Studies in biomimetic alkaloid syntheses. 4. An alternative route to secodine intermediates providing syntheses of minovine, vincadifformine, ervinceine, and N(a)-methylervinceine. J. Org. Chem. 1979, 44, 2477-2480.
28. 2-adrenoceptor antagonist. J. Med. Chem. 1985, 28, 1756-1759.
29. Guenjoer, T.; Malabre, P.; Teulon, J. M. New synthesis of 1-substituted 3-(2-aminoethyl)indoles. Synth. Commun. 1994, 24, 2247-2256.
30. Zelesko, M. J.; McComsey, D. F.; Hageman, W. E.; Nortey, S. O.; Baker, C. A.; Maryanoff, B. E. Cardiac-slowing amidines containing the 3-thioindole group. Potential antianginal agents. J. Med. Chem. 1983, 26, 230-237.
31. Schindler, W. 6-Isotryptaminopurine. Helv. Chim. Acta 1957, 40, 2156-2159.
32. Wright, W. B., Jr.; Brabander, H. J. Central nervous system depressants. IV. 2-Aminoalkyl-1,2-dihyro-3H-imidazo[1,5-a]indol-3-ones. J. Med. Chem. 1968, 11, 1164-1167.
33. 2 tetradentate ligands suitable for nuclear medicine applications. Synlett 2001, 126-128.
34. McClure, J. R.; Custer, J. H.; Schwarz, H. D.; Lill, D. A. Synthesis of annelated imidazoles and benzimidazoles. Synlett 2000, 710-712.
35. Kolle, D.; Brosch, G.; Lechner, T.; Lusser, A.; Loidl, P. Biochemical methods for analysis of histone deacetylases. Methods: A Companion to Methods in Enzymology 1998, 15, 323-331.